Found: 17
Select item for more details and to access through your institution.
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 6, p. 1807, doi. 10.1007/s10637-020-00945-y
- By:
- Publication type:
- Article
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
- Published in:
- American Journal of Hematology, 2009, v. 84, n. 4, p. 228, doi. 10.1002/ajh.21365
- By:
- Publication type:
- Article
Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration.
- Published in:
- BJU International, 2021, v. 128, n. 5, p. 607, doi. 10.1111/bju.15434
- By:
- Publication type:
- Article
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 7, p. 611, doi. 10.1007/s40261-022-01170-6
- By:
- Publication type:
- Article
Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002.
- Published in:
- Oncologist, 2023, v. 28, p. S10, doi. 10.1093/oncolo/oyad216.016
- By:
- Publication type:
- Article
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
- Published in:
- Oncologist, 2023, v. 28, n. 1, p. 72, doi. 10.1093/oncolo/oyac186
- By:
- Publication type:
- Article
Longitudinal Evaluation of Circulating Tumor DNA Using Sensitive Amplicon-Based Next-Generation Sequencing to Identify Resistance Mechanisms to Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. e406, doi. 10.1093/oncolo/oyac037
- By:
- Publication type:
- Article
Real‐World Assessment of Clinical Outcomes Among First‐Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
- Published in:
- Oncologist, 2020, v. 25, n. 5, p. 422, doi. 10.1634/theoncologist.2019-0605
- By:
- Publication type:
- Article
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 6, p. 840, doi. 10.1002/cncr.33328
- By:
- Publication type:
- Article
Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis.
- Published in:
- World Journal of Urology, 2020, v. 38, n. 9, p. 2227, doi. 10.1007/s00345-019-03003-2
- By:
- Publication type:
- Article
Highlights in Metastatic Urothelial Carcinoma From the European Society for Medical Oncology Congress 2023: Commentary.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, p. 15
- By:
- Publication type:
- Article
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 3, p. 775, doi. 10.1007/s00262-022-03274-6
- By:
- Publication type:
- Article
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1795, doi. 10.1007/s00262-021-03128-7
- By:
- Publication type:
- Article
Characterization of FOLH1 Expression in Renal Cell Carcinoma.
- Published in:
- Cancers, 2024, v. 16, n. 10, p. 1855, doi. 10.3390/cancers16101855
- By:
- Publication type:
- Article
The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma.
- Published in:
- Cancers, 2022, v. 14, n. 24, p. 6018, doi. 10.3390/cancers14246018
- By:
- Publication type:
- Article
One Size Fits Some: Approaching Rare Malignancies of the Urinary Tract.
- Published in:
- Current Treatment Options in Oncology, 2024, v. 25, n. 2, p. 206, doi. 10.1007/s11864-024-01187-3
- By:
- Publication type:
- Article
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article